John Lewis, MD
Glaucoma Specialist · Mesa, AZNPI 1851364814
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $46,852 of the $60,558 with a category attached, or 77.4%. 14 manufacturers reported payments, led by Aerie Pharmaceuticals, Inc. at 40.9% of the total. Reporting peaked in 2019 at $18,719 and has fallen 77.5% since, to $4,205 in 2025.
Across 302 payments — averaging $200.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$25K
- Bausch & Lomb Americas Inc.$15K
- AbbVie$15K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$3K
- Alcon$936
- Novartis$324
- plus $835 from 8 others
What the payments were for
- Consulting fees$2,3954%
- Speaking & faculty fees$46,85277%
- Travel & lodging$3,5446%
- Food & beverage$7,76813%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 77 | $24,761 |
| Bausch & Lomb Americas Inc. | 32 | $15,441 |
| AbbVie(2 entities) | 109 | $15,364 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $2,898 |
| Alcon | 42 | $936 |
| Novartis | 11 | $324 |
| Glaukos Corporation | 2 | $276 |
| Sight Sciences, Inc. | 2 | $174 |
| Sun Pharmaceutical Industries Inc. | 8 | $160 |
| Thea Pharma Inc. | 4 | $62 |
| Medline Industries LP | 1 | $58 |
| Amgen | 2 | $38 |
| Akorn Operating Company LLC | 2 | $37 |
| Kala Pharmaceuticals, Inc. | 2 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$23,435
- Rhopressa$18,689
- VYZULTA$17,839
- LUMIGAN$12,862
- COMBIGAN$9,641
- ALPHAGAN P$1,575
- iStent inject W$253
- KXL System$253
- DURYSTA$241
- TRAVATAN Z$240
- Voyager DSLT$122
- XEN GLAUCOMA TREATMENT SYSTEM$119
- OMNI$116
- SIMBRINZA$113
- LOTEMAX SM$101
- MIEBO$101
How this compares
Too few glaucoma specialist providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 946 | $524,571 |
| VyzultaLatanoprostene Bunod | 255 | $135,874 |
| RocklatanNetarsudil Mesylat/Latanoprost | 209 | $127,062 |
| CombiganBrimonidine Tartrate/Timolol | 253 | $120,240 |
| RhopressaNetarsudil Mesylate | 151 | $94,587 |
| Alphagan PBrimonidine Tartrate | 113 | $46,703 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 113 | $35,486 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 99 | $24,760 |
| Brinzolamide | 107 | $18,470 |
| Travoprost | 133 | $17,638 |
| Latanoprost | 1,462 | $16,623 |
| Brimonidine Tartrate | 626 | $12,305 |
| Dorzolamide Hcl | 557 | $11,270 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 586 | $8,842 |
| Timolol Maleate | 781 | $8,324 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $15,364 | $691,5141,312 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $24,761 | $221,649360 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $15,441 | $135,874255 claims |
| AlconSimbrinza | $936 | $35,486113 claims |
| NovartisTravatan Z | $324 | $4,88216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Mesa
- Robert SpurnyMesa$5K
- David KayMesa$4K
- Christine FunkePhoenix$255K
- Max KimPhoenix$10K
- Trenton BowenGilbert$4K
- Michael CampionScottsdale$3K
- Neil AtodariaPhoenix$3K
- Sunil DeokuleYuma$2K
- Tara GolischPhoenix$2K
- Brian ChangCottonwood$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.